It CAN capture a single cell. If it can ISOLATE single cells, I can't even imagine how expensive the test would be to manufacture and administer. How can you guarantee that your sample of blood contains those few metastatic cancer cells? The only way to guarantee that you don't have cancer with this test is to literally wash the cancer trapping portions of the plate with the patient's entire blood volume. THIS test has worse screening issues than Onko-Sure. So, for this test to be worth the most likely high price you would probably have to somehow guarantee that there will be cancerous cells in the blood sample that is drawn for the test. These points are inarguable.
Furthermore, the argument of why a company would spend X millions of dollars on an "ineffective" test simply is not valid. You don't believe in ability of the Onko-Sure kit and they spent x millions of dollars on their test. Numerous companies spend x millions of dollars developing tests that may not work very well.
It is a fact that metastasis primarily occurs in the later stage of cancer progression. If you are looking for metastatic cells then that would be in...the LATER stage of cancer progression. It is possible that they are aiming this test particularly at cancer identification. In which case it would be an excellent test. However, it still cannot be effective in early stage cancer detection or identification. If it was meant for that, don't you think J & J would have touted it as a benefit in their press release? They can't because their test simply cannot due that. This is all basic cancer biology.
News 
Market Data 
Discover 
